Lee HY, Shin J, Kim GH, et al. 2018 Korean Society of Hypertension Guidelines for the management of hypertension: part II-diagnosis and treatment of hypertension. Clin Hypertens. 2019;25:20.
Williams B, Mancia G, Spiering W, et al. ESC Scientific Document Group . 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021–104.
Johnson K, Oparil S, Davis BR, et al. Prevention of Heart Failure in Hypertension-Disentangling the Role of Evolving Left Ventricular Hypertrophy and Blood Pressure Lowering: The ALLHAT Study. J Am Heart Assoc. 2019;8(8):e011961.
Lalande S, Johnson BD. Diastolic dysfunction: a link between hypertension and heart failure. Drugs Today (Barc). 2008;44(7):503–13.
Neaton JD, Grimm RH Jr, Prineas RJ, et al. Treatment of mild hypertension study. Final results. Treatment of mild hypertension study research group. JAMA. 1993;270(6):713–24.
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2002;288(23):2981–97.
Davis BR, Piller LB, Cutler JA, et al. Role of diuretics in the prevention of heart failure: the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Circulation. 2006;113(18):2201–10.
Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the hypertension Detection and follow-up program. Prevention and reversal of left ventricular hypertrophy with antihypertensive drug therapy. Hypertension. 1985;7:105–12.
Ofili EO, Cohen JD, St Vrain JA, et al. Effect of treatment of isolated systolic hypertension on left ventricular mass. JAMA. 1998;279:778–80.
Ernst ME, Neaton JD, Grimm RH Jr, et al. Long-term effects of chlorthalidone versus hydrochlorothiazide on electrocardiographic left ventricular hypertrophy in the multiple risk factor intervention trial. Hypertension. 2011;58:1001–7.
Kahan T. The importance of left ventricular hypertrophy in human hypertension. J Hypertens Suppl. 1998 Sep;16(7):S23–9.
Dahlöf B, Sever PS, Poulter NR, et al. ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366(9489):895–906.
Barron AJ, Hughes AD, Sharp A, et al. ASCOT investigators. Long-term antihypertensive treatment fails to improve E/e' despite regression of left ventricular mass: an Anglo-Scandinavian cardiac outcomes trial substudy. Hypertension. 2014;63(2):252–8.
Davis BR, Kostis JB, Simpson LM, et al. Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Circulation. 2008;118(22):2259–67.
Cleland JG, Tendera M, Adamus J, et al. PEP-CHF investigators. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27(19):2338–45.
Yusuf S, Pfeffer MA, Swedberg K, et al. CHARM investigators and committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial. Lancet. 2003;362(9386):777–81.
Massie BM, Carson PE, McMurray JJ, et al. I-PRESERVE investigators. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359(23):2456–67.
Roush GC, Buddharaju V, Ernst ME, et al. Chlorthalidone: mechanisms of action and effect on cardiovascular events. Curr Hypertens Rep. 2013;15:514–21.
Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, Detection, evaluation, and Management of High Blood Pressure in adults: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Hypertension. 2018;71(6):e13–e115.
Williams B, Mancia G, Spiering W, ESC Scientific Document Group, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021–104.
Nerenberg KA, Zarnke KB, Leung AA, et al. Hypertension Canada. Hypertension Canada’s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children. Can J Cardiol. 2018;34(5):506–25.
National Heart Foundation of Australia. Guideline for the diagnosis and management of hypertension in adults – 2016. Melbourne: National Heart Foundation of Australia; 2016.
Pareek AK, Mehta RT, Purkait I, et al. Diabetic Hypertensives and diastolic dysfunction: use of Calcium Channel blockers-a clinical concern. JACC Heart Fail. 2017;5(11):850–1.